ubs upgrade to buy

Sorry if already mentioned, rather a different view to the CIMB note published the same day.

UBS 09-Jan-14

The company's Q2 update surprised to the upside, in particular dose sales, and while UBS analysts are reluctant to extrapolate this latest report into infinity, they do believe there was enough support in the quarterly update to assume a higher growth rate shall remain in place this financial year.

UBS has lifted forecasts. This has led to a jump in the price target, to $15.00 from $12.60. The rating has been lifted to Buy from Neutral. Note DPS forecasts have been increased too.

CIMB Securities 09-Jan-14

The company's Q2 sales report surprised to the upside and CIMB analysts have slightly lifted forecasts. However, they also point out medium term growth for Sirtex is predicated on favourable clinical outcomes, which carries a lot of risk. CIMB believes this risk is currently not reflected in the share price.

While acknowledging the shares are likely to find support on the back of the Q2 report, CIMB sticks to its Sell rating. Price target is $11.53.